Skip to main content

Bradbury Daniel's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Dec 1, 2023

Accession no.
0001447362-23-000157
Filed
Dec 1, 2023
Trade date
Nov 29-30, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions. Open-market sales total $593.6K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bradbury DanielCIK 0001236397Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 29, 2023Common StockSSaleDisposed−10,406$20.13F2−$209,472.7886,788Indirect
Nov 29, 2023Common StockSSaleDisposed−3,468$20.13F2−$69,810.8460,197Indirect
Nov 29, 2023Common StockSSaleDisposed−3,468$20.13F2−$69,810.8460,222Indirect
Nov 30, 2023Common StockSSaleDisposed−7,307$20.08F6−$146,724.5679,481Indirect
Nov 30, 2023Common StockSSaleDisposed−2,436$20.08F6−$48,914.8857,761Indirect
Nov 30, 2023Common StockSSaleDisposed−2,436$20.08F6−$48,914.8857,786Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $20.010 to $20.320, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $20.000 to $20.245, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)